Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsPreferred Shares RepurchasedShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Long-Term Debt Repayments (2021 - 2022)

PharmaCyte Biotech (PMCB) has disclosed Long-Term Debt Repayments for 2 consecutive years, with $50805.0 as the latest value for Q2 2022.

  • Quarterly Long-Term Debt Repayments rose 200.0% to $50805.0 in Q2 2022 from the year-ago period, while the trailing twelve-month figure was $38169.0 through Apr 2022, up 402.07% year-over-year, with the annual reading at $50805.0 for FY2022, 18.63% down from the prior year.
  • Long-Term Debt Repayments for Q2 2022 was $50805.0 at PharmaCyte Biotech, up from -$50805.0 in the prior quarter.
  • The five-year high for Long-Term Debt Repayments was $50805.0 in Q2 2022, with the low at -$50805.0 in Q2 2021.